303 related articles for article (PubMed ID: 15132136)
1. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population.
Hsiao HH; Yang MY; Chang JG; Liu YC; Liu TC; Chang CS; Chen TP; Lin SF
Cancer Chemother Pharmacol; 2004 May; 53(5):445-51. PubMed ID: 15132136
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients.
He YF; Wei W; Zhang X; Li YH; Li S; Wang FH; Lin XB; Li ZM; Zhang DS; Huang HQ; Hu B; Jiang WQ
J Clin Pharm Ther; 2008 Jun; 33(3):307-14. PubMed ID: 18452418
[TBL] [Abstract][Full Text] [Related]
3. Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer.
Uzunkoy A; Dilmec F; Ozgonul A; van Kuilenburg AB; Akkafa F
Anticancer Res; 2007; 27(6B):3899-902. PubMed ID: 18225548
[TBL] [Abstract][Full Text] [Related]
4. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB
Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084
[TBL] [Abstract][Full Text] [Related]
5. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
Ofverholm A; Arkblad E; Skrtic S; Albertsson P; Shubbar E; Enerbäck C
Clin Biochem; 2010 Feb; 43(3):331-4. PubMed ID: 19822137
[TBL] [Abstract][Full Text] [Related]
6. Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population.
Ben Fredj R; Gross E; Chouchen L; B'Chir F; Ben Ahmed S; Neubauer S; Kiechle M; Saguem S
C R Biol; 2007 Oct; 330(10):764-9. PubMed ID: 17905396
[TBL] [Abstract][Full Text] [Related]
7. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
Ezzeldin HH; Lee AM; Mattison LK; Diasio RB
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8699-705. PubMed ID: 16361556
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
9. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
Gross E; Ullrich T; Seck K; Mueller V; de Wit M; von Schilling C; Meindl A; Schmitt M; Kiechle M
Hum Mutat; 2003 Dec; 22(6):498. PubMed ID: 14635116
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
Amstutz U; Farese S; Aebi S; Largiadèr CR
J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829
[TBL] [Abstract][Full Text] [Related]
11. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.
Ezzeldin H; Johnson MR; Okamoto Y; Diasio R
Clin Cancer Res; 2003 Aug; 9(8):3021-8. PubMed ID: 12912951
[TBL] [Abstract][Full Text] [Related]
12. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency.
Ezzeldin H; Okamoto Y; Johnson MR; Diasio RB
Anal Biochem; 2002 Jul; 306(1):63-73. PubMed ID: 12069415
[TBL] [Abstract][Full Text] [Related]
13. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH
Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
[TBL] [Abstract][Full Text] [Related]
14. [Mutations in the dihydropyrimidine dehydrogenase gene and their role in 5-fluororuracil intolerance].
Gross E; Seck K; Kiechle M
Zentralbl Gynakol; 2002 Dec; 124(12):574-9. PubMed ID: 12822071
[TBL] [Abstract][Full Text] [Related]
15. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.
Johnson MR; Wang K; Diasio RB
Clin Cancer Res; 2002 Mar; 8(3):768-74. PubMed ID: 11895907
[TBL] [Abstract][Full Text] [Related]
16. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
van Kuilenburg AB
Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
van Kuilenburg AB; De Abreu RA; van Gennip AH
Ann Clin Biochem; 2003 Jan; 40(Pt 1):41-5. PubMed ID: 12542909
[TBL] [Abstract][Full Text] [Related]
19. Sequence analysis of the 5'-flanking regions of human dihydropyrimidine dehydrogenase gene: identification of a new polymorphism related with effects of 5-fluorouracil.
Hasegawa T; Kim HS; Fukushima M; Wataya Y
Nucleosides Nucleotides Nucleic Acids; 2005; 24(4):233-42. PubMed ID: 16021908
[TBL] [Abstract][Full Text] [Related]
20. Dihydropyrimidine dehydrogenase (DPYD) gene c.1627A>G A/G and G/G genotypes are risk factors for lymph node metastasis and distant metastasis of colorectal cancer.
Zeng J; Wu H; Huang Q; Li J; Yu Z; Zhong Z
J Clin Lab Anal; 2021 Nov; 35(11):e24023. PubMed ID: 34612540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
